Free Trial
NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Mineralys Therapeutics logo
$14.49 -0.15 (-1.02%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$14.49 0.00 (0.00%)
As of 07/11/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Key Stats

Today's Range
$14.30
$14.94
50-Day Range
$13.45
$16.66
52-Week Range
$8.24
$18.38
Volume
442,534 shs
Average Volume
556,098 shs
Market Capitalization
$944.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.25
Consensus Rating
Moderate Buy

Company Overview

Mineralys Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

MLYS MarketRank™: 

Mineralys Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 587th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mineralys Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mineralys Therapeutics is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mineralys Therapeutics is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mineralys Therapeutics has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mineralys Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.89% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 24.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Mineralys Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mineralys Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.89% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 24.31%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Mineralys Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $338,934.00 in company stock.

  • Percentage Held by Insiders

    25.56% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mineralys Therapeutics' insider trading history.
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

MLYS Stock Analysis - Frequently Asked Questions

Mineralys Therapeutics' stock was trading at $12.31 on January 1st, 2025. Since then, MLYS shares have increased by 17.7% and is now trading at $14.49.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.23.
Read the conference call transcript
.

Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share.

Top institutional investors of Mineralys Therapeutics include Swedbank AB (0.59%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman.
View institutional ownership trends
.

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/12/2025
Today
7/13/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLYS
CIK
1933414
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$15.00
Potential Upside/Downside
+122.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$177.81 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-71.15%
Return on Assets
-65.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.48
Quick Ratio
26.48

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.84 per share
Price / Book
3.77

Miscellaneous

Outstanding Shares
65,175,000
Free Float
48,516,000
Market Cap
$944.39 million
Optionable
Optionable
Beta
-0.30
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:MLYS) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners